Memantine
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Memantine (3,5-dimethyladamantan-1-amine) is a synthetic dissociative of the adamantane class. It is a close structural relative of amantadine, with two extra methyl groups that increase potency and receptor selectivity. It blocks glutamate receptors in the brain, dampening excessive neuronal signaling and producing the cognitive disconnection characteristic of dissociatives.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
ketamine, dextromethorphan, PCP +2 moreketamine, dextromethorphan, PCP, nitrous oxide, MXE show less
Synthesized by Eli Lilly in the mid-1960s as a potential blood-sugar-lowering drug, memantine failed as an antidiabetic before Merz identified its brain effects and launched it in Germany in 1989 for dementia.[2] The FDA approved it in October 2003 as Namenda for moderate-to-severe Alzheimer's disease.[3] It is now among the most widely prescribed neurological drugs in the United States, with active clinical research into OCD, PTSD, and chemotherapy-related cognitive decline.[4][5]
Subjective effects include cognitive disconnection, emotional suppression, perceptual flattening, mild dissociation, and a clear-headed detachment from bodily awareness. The experience is defined by its extraordinary duration — a slow-building, multiday cognitive detachment closer to a sustained mental haze than the acute dissociative plunge of ketamine.[6] Prolonged depersonalization, confusion, and a persistent fear that normal cognition will not return are characteristic unwanted effects.
Memantine produces low to negligible dependence, and its safety at approved doses matches placebo in clinical trials.[7] The main danger at higher doses is pharmacokinetic: the 60–80 hour half-life locks users into multiday experiences, and urine alkalinizers — antacids, baking soda — can increase drug exposure by up to 80%,[8] making dose control unpredictable. Clinical data are robust at therapeutic doses but nonexistent above 20 mg — the entire recreational range falls within an uncharacterized evidence gap.
History[edit]
Discovery
Memantine was synthesized by Eli Lilly between 1963 and 1966 as a potential blood-sugar-lowering drug.[9] It failed as an antidiabetic, and its brain effects went unrecognized for over a decade until the German company Merz identified them. Clinical trials began in 1986,[9] and Merz launched it in Germany in 1989 under the names Akatinol and Axura — years before its mechanism was fully understood.[2][1]
Clinical significance
In the late 1990s, researchers characterized memantine as an NMDA glutamate receptor antagonist.[10] Lipton and colleagues explained why it worked where similar drugs had failed: its fast, shallow binding blocked pathological signaling while sparing the brief channel openings needed for normal brain function.[11][12] This understanding — the "uncompetitive/fast off-rate" model — became foundational to how this class of drugs is designed.[1]
Regulatory approval and modern use
The European Medicines Agency approved memantine for moderate-to-severe Alzheimer's disease in 2002,[2] and the FDA followed in October 2003 as Namenda.[3] The pivotal trial showed cognitive and functional benefits at 20 mg/day over 28 weeks.[7] By 2022, over 114 branded formulations had been registered globally,[9] including the fixed-dose combination Namzaric (memantine + donepezil).[13]
The name memantine derives from its chemistry: methyl + amine + adamantane. The compound occupies an unusual cultural position — a mass-market prescription drug with a quiet secondary life as one of the least recreational dissociatives.
Chemistry[edit]
Memantine belongs to the adamantane chemical family — a rigid, cage-like carbon structure formed from three fused rings. Its closest relative is amantadine (the unsubstituted parent compound, used for influenza and Parkinson's disease). Two extra methyl groups on the cage increase memantine's potency and modify how it interacts with glutamate receptors.[10]
Its molecular formula is C₁₂H₂₁N (molecular weight 179.30 g/mol), with no chirality centers — no mirror-image forms exist.[14] The amine group carries a positive charge at body pH, enabling it to enter and block the glutamate receptor channel.[14] Memantine hydrochloride is a white crystalline powder.[9]
Pharmacology[edit]
Mechanism of action
Memantine blocks glutamate receptors in the brain by entering the receptor's channel pore only after it has been opened.[11][3] It selectively targets pathological overactivation — the sustained low-level glutamate flood seen in neurodegeneration — while leaving brief normal channel openings mostly intact.[12][1] This selectivity is why memantine is clinically tolerable where other glutamate blockers cause serious neurological adverse effects.[15][16]
Secondary targets
Beyond glutamate receptors, memantine also blocks serotonin receptors and nicotinic acetylcholine receptors at clinically relevant concentrations.[8][17] A 2025 study identified an additional action on calcium-permeable receptors through an entirely different mechanism.[18]
Pharmacokinetics
Memantine is absorbed almost completely after swallowing and is barely processed by the liver — about 48% exits the body unchanged in urine.[8] Its half-life is 60–80 hours, meaning one dose continues acting for days. Anything that makes urine more alkaline — antacids, baking soda, some kidney conditions — slows clearance by roughly 80%,[8] substantially increasing drug exposure.
Neuroscience[edit]
Cortical processing
Memantine selectively reduces feedback processing in the brain — the loops by which higher cortical regions elaborate and amplify incoming signals.[19] This differs from blocking basic sensory input: it dampens the brain's capacity to attend to and interpret complex stimuli.[20] Direct brain recording confirmed that memantine reduces how strongly the brain responds to unexpected stimuli, consistent with NMDA inhibition.[21]
Excitotoxicity and neuroprotection
Memantine's therapeutic rationale rests on the excitotoxicity model: in neurodegeneration, chronically elevated glutamate overstimulates receptors, floods neurons with calcium, and triggers cell death. Memantine's fast, reversible binding dampens this pathological flood while still allowing the brief channel openings needed for learning and memory.[11][1] Studies of brain tissue from treated Alzheimer's patients suggest chronic use may partially restore the balance between excitatory and inhibitory signaling that neurodegeneration disrupts.[22]
- Why does memantine lack the rapid antidepressant effect seen with ketamine, despite both blocking NMDA receptors? Whether the answer lies in binding behavior, pharmacokinetics, or an unidentified mechanism remains unclear.
- Does the recently discovered action on calcium-permeable receptors[18] contribute to neuroprotection at therapeutic doses in the human brain?
- What is the dose-response curve for dissociative effects in healthy people? No controlled studies have examined memantine above therapeutic doses — the transition to dissociative effects is documented only in community reports.
Subjective Effects[edit]
At supratherapeutic doses, memantine produces a dissociative state that is primarily cognitive rather than perceptual. Onset builds gradually over two to three hours. The dominant quality is a clear-headed disconnection from emotional reactivity and bodily awareness — without the immersive visual distortion or euphoric rush of faster-acting dissociatives.
Compared to ketamine or dextromethorphan, memantine dissociation is consistently described as more lucid but less rewarding.[6] The multiday duration and slow onset make it the least acute — and least recreational — NMDA antagonist in common use.
Effect Grid
At 70–110 mg, a clear dissociative state establishes itself. Bodily dissociation and cognitive disconnection are prominent — a felt separation between mind and body that distinguishes this from lighter doses. Derealization and depersonalization emerge reliably. Visual perception shifts: visual haze, mild drifting, depth perception distortion. Auditory distortion and suppression are common. Memory suppression becomes noticeable, and thought deceleration is pronounced.
Physical effects include moderate dizziness, motor control impairment, vestibular distortion, and pain suppression. Nausea occurs in a minority. Stimulation may paradoxically coexist with cognitive slowing. Constipation is possible.
The experience lasts 18–24+ hours at full intensity, with cognitive residue extending 1–2 additional days. Sleep is frequently disrupted for 12–24 hours. Functional impairment persists well beyond subjective resolution — plan for 48+ hours of limited capacity.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sensory deprivation · Vestibular distortion · Auditory distortion · Auditory misinterpretation · Touch suppression · Visual acuity suppression · Visual haze / noise · Dreaming enhancement · Tinnitus · Internal hallucinations · Visual processing suppression · Auditory hallucinations · External hallucinations
Touch suppression · Visual acuity suppression · Visual haze / noise · Dreaming enhancement · Tinnitus · Internal hallucinations · Visual processing suppression · Auditory hallucinations · External hallucinations
Body high · Body schema distortion · Nystagmus (eye wobbles) · Pain suppression · Physical fatigue · Bodily heaviness · Bodily lightness · Headache · Muscle relaxation · Restlessness · Spontaneous body sensations · Constipation · Dry mouth · Insomnia · Pupil dilation · Stimulation · Tingling / electric sensations · Vomiting · Abnormal heartbeat · Trembling · Bodily dissociation · Tactile hallucination
Pain suppression · Physical fatigue · Bodily heaviness · Bodily lightness · Headache · Muscle relaxation · Restlessness · Spontaneous body sensations · Constipation · Dry mouth · Insomnia · Pupil dilation · Stimulation · Tingling / electric sensations · Vomiting · Trembling · Bodily dissociation · Tactile hallucination
Information processing suppression · Memory suppression · Thought disorganization · Analysis suppression · Cognitive fatigue · Memory fragmentation · Thought deceleration · Cognitive dysphoria · Cognitive euphoria · Language suppression · Suggestibility enhancement · Thought loops · Amnesia · Delirium · Delusions
Analysis suppression · Cognitive fatigue · Memory fragmentation · Thought deceleration · Cognitive dysphoria · Cognitive euphoria · Language suppression · Thought loops · Amnesia · Delirium · Delusions
Irritability · Anxiety suppression · Emotional lability
Social disconnection · Disinhibition · Compulsive behavior reduction · Cognitive disconnection · Boundary dissolution · Ego dissolution
Boundary dissolution · Ego dissolution
Timeline
Gradual awareness of altered state. Subtle cognitive slowing and a faint sense of mental cushioning emerge. Very slow build relative to other dissociatives — consistent with oral Tmax of 3–7 hours.
Progressive dissociative deepening. Body sensation changes, emerging bodily lightness and mild derealization. Perceptual shifts begin — faint visual haze, auditory changes.
Maximum dissociative intensity. Cognitive disconnection, bodily dissociation, and perceptual distortions at their strongest. Memory suppression and analysis suppression are prominent.
Sustained dissociative state with gradual modulation. Effects remain strong but stable — the long half-life produces an extended plateau uncommon among NMDA antagonists. Cognitive function begins slow recovery.
Slow tapering of dissociative effects over many hours. Cognitive function gradually returns. Motor coordination improves but remains subtly impaired.
Residual cognitive alteration, mild dissociative quality, and possible fatigue driven by the 60–80 hour elimination half-life. Subtle perceptual and cognitive effects may persist for days.
⚠ Do not drive or operate heavy machinery for at least 48 hours after use — memantine's long half-life means residual impairment may persist for days.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- Negligible
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- ketamine · dextromethorphan · PCP
Toxicity
Therapeutic dose safety
At approved doses (5–20 mg/day), adverse event rates match placebo.[7][23] Common side effects include dizziness, headache, confusion, diarrhea, constipation, and sedation.[8] Rare post-marketing reports include seizures, severe skin reactions, and cardiac events.[8]
Overdose
safety citation needed The exact toxic dose in humans has not been established. The only published overdose case involved 2,000 mg — roughly 100 times the standard daily dose.[24] The person lost consciousness, developed seizures and a rapid heart rate, and required blood-filtering treatment (plasmapheresis) before making a full recovery.
No antidote exists. Standard treatment includes benzodiazepines for seizures and plasmapheresis for severe cases.[24]
Supratherapeutic dose gap
safety citation needed No controlled human safety data exist above 20 mg. The entire recreational dose range falls within this evidence gap — between the therapeutic ceiling and the single documented massive overdose.
Psychological risks
At therapeutic doses, hallucinations, confusion, and aggressive behavior are documented side effects.[8] At higher doses, the primary psychological risk is duration: dissociative states can last one to three days, and users describe fearing that normal thinking will not return.[6]
Tolerance & Dependence
Tolerance to therapeutic effects has not been observed in trials lasting up to 28 weeks.[7] Memantine has low to negligible dependence potential — its slow onset and multiday duration act as intrinsic deterrents to compulsive use.[6] No withdrawal has been documented, and cross-tolerance with other dissociatives is plausible but unconfirmed.
Drug interactions
Pharmacokinetic
The most significant interaction is with urinary alkalinizers — antacids, sodium bicarbonate, and carbonic anhydrase inhibitors. These reduce memantine's kidney clearance by approximately 80%, potentially converting a safe dose into a dangerous one.[8] Urinary acidifiers (ammonium chloride) have the opposite effect, increasing clearance and reducing the drug's effects. Because memantine barely enters the liver, CYP-based drug interactions are negligible.[8][25]
Pharmacodynamic
Combining memantine with other NMDA blockers — ketamine, dextromethorphan, amantadine, nitrous-oxide — additively increases the risk of confusion, dissociation, and psychosis.[8]
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are pharmacodynamically complementary — the combination is clinically approved but may increase side effect rates.[13] Some enhancement of L-DOPA effects is possible through glutamate–dopamine circuit interaction.[10][1]
Contraindications
Allergy to memantine is an absolute contraindication.[8] Severe kidney impairment roughly doubles blood levels and half-life — use requires dose reduction and careful monitoring. Other NMDA antagonists increase neuropsychiatric risk and require caution.[8]
Conditions producing alkaline urine — kidney tubular acidosis, severe urinary infections, chronic antacid use — reduce clearance by ~80% and can convert a tolerable dose into a dangerous one.[8] Seizure disorders warrant caution — seizures are documented in overdose and listed as a rare side effect.[24][8]
Harm Reduction[edit]
Forms & Identification
Memantine circulates only as pharmaceutical tablets, capsules, and oral solution. The key risk is not adulteration but dose verification: tablets from different manufacturers come in different strengths (5 mg, 10 mg, 14 mg, 21 mg, 28 mg). Confirm the exact strength marked on the tablet or packaging before use.
Because memantine is a legal prescription drug, reagent testing is less relevant than with unregulated substances. The primary source of unpredictability is pharmacokinetic — urinary pH, kidney function, and individual variation produce wide differences in how intensely and how long the drug acts.
Guidelines
- Start low. Near-complete bioavailability and multiday duration mean dosing errors compound over days, not hours. Begin well below the intended target.
- Allow full onset time. Peak effects take 3–7 hours. Do not redose before at least 8 hours have passed — stacking doses with a 60–80 hour half-life causes unpredictable accumulation.
- Avoid urinary alkalinizers. Antacids, sodium bicarbonate, and alkaline diets reduce clearance by up to 80%. Avoid these before or during use.
- Clear the schedule. Block at minimum 48 hours with no driving, heavy machinery, or responsibilities requiring full cognitive function.
- Hydrate and eat normally. The multiday timeline makes sustained self-care essential.
- Do not use with impaired kidney function. Reduced clearance roughly doubles blood levels and extends the already long duration.
Set & Setting
Memantine's defining practical challenge is duration. At supratherapeutic doses, effects persist for one to three days — a multiday commitment, not an evening experience. Planning must account for obligations, driving, and cognitive demands across the entire window.
A familiar environment with access to food, water, and sleep space is essential. The clear-headed character of memantine dissociation can create a false sense of normalcy — cognitive impairment may be deeper than it feels. A sober companion who understands the timeline is strongly recommended for first experiences.
Aftercare & integration. The multiday duration means the boundary between "experience" and "aftercare" is blurred. Residual cognitive blunting and emotional flatness may persist for two to four days after peak effects resolve.
During this period, prioritize sleep, regular meals, and low-demand activities. Avoid significant decisions until baseline cognition clearly returns. Journaling helps separate drug-state insights from residual dissociative thinking. If depersonalization or a sense of unreality persists beyond one week, consult a healthcare provider.
Recovery & Support
Memantine dependence is rare, but any pattern of escalating recreational use warrants honest self-assessment. If use is driven by a desire to escape emotional pain or cognitive distress, professional support addresses the underlying need more effectively than repeated dissociative experiences.
Resources for dissociative-related concerns include SAMHSA's National Helpline (1-800-662-4357), local addiction services, and online harm reduction communities. If memantine was obtained via prescription diversion, discussing this with a prescriber reduces long-term risk.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Seizures or convulsions
- Unresponsiveness or loss of consciousness
- Severe confusion progressing to inability to communicate
- Rapid heart rate with chest pain or difficulty breathing
- Sustained high blood pressure (throbbing headache, visual disturbances)
Immediate steps:
- Call emergency services if any of the above signs are present.
- Place an unconscious person in the recovery position.
- Do not induce vomiting.
- Do not attempt to "walk off" seizures — protect the head, clear the area, time the seizure.
- Keep the person calm and in a quiet environment if conscious but severely confused.
What to tell the dispatcher: name the substance (memantine), the amount taken, when it was taken, and current symptoms. Note the extremely long half-life (60–80 hours) — effects will not resolve quickly. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific antidote exists. Hospital treatment may include benzodiazepines for seizures and plasmapheresis for severe overdose.
Legal Status[edit]
Memantine is a prescription-only pharmaceutical approved for moderate-to-severe Alzheimer's disease in all major jurisdictions. It is not classified as a controlled substance under any national drug scheduling framework.[6]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Prescription drug (not scheduled DEA I–V) | FDA-approved October 2003 (NDA 21-627, Namenda). Off-label prescribing legal. 145th most prescribed drug in 2023 (>3 million prescriptions)[3] |
| European Union | Prescription-only medicine | EMA-approved since 2002 for moderate-to-severe AD. Not scheduled as a controlled substance in any EU member state[2] |
| United Kingdom | Prescription-only medicine (POM) | Not scheduled under the Misuse of Drugs Act 1971. Available on NHS for Alzheimer's diseasecitation needed |
| Canada | Prescription-only | Licensed for moderate-to-severe AD. Not a controlled substance. Provincial reimbursement variescitation needed |
| Australia | Schedule 4 (Prescription Only Medicine) | TGA-listed. Not scheduled as a controlled drugcitation needed |
Memantine is not detected by standard immunoassay drug screening panels. Identification requires gas chromatography–mass spectrometry (GC-MS) or liquid chromatography–tandem mass spectrometry (LC-MS/MS).citation needed
Legal status is subject to change and varies by jurisdiction. This information is not legal advice.
references
- [1]
- [2] ^abcdKilpatrick GJ, Tilbrook GS (2002) Memantine. Merz. — Current Opinion in Investigational Drugs PMID:12090556
- [3] ^abcdMöbius HJ, Stöffler A, Graham SM (2004) Memantine hydrochloride: pharmacological and clinical profile — Drugs of Today PMID:15510240
- [4] ^Sani G, Serra G, Kotzalidis GD, et al. (2012) The role of memantine in the treatment of psychiatric disorders other than the dementias — CNS Drugs doi:10.2165/11634390-000000000-00000
- [5] ^Joshi G, Gönenc A, DiSalvo M, Faraone SV, et al. (2025) Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder: A Randomized Clinical Trial — JAMA Network Open doi:10.1001/jamanetworkopen.2025.34927
- [6]